Side effect profile of hepatitis C treatment with peginterferon alpha-2b and ribavarin
Keywords:Hepatits C, Neuropsychiatric, Pegylated interferon α-2b, Ribavirin
Background: The major types of side effects include fatigue, influenza-like symptoms, gastrointestinal disturbances, neuropsychiatric symptoms and hematologic abnormalities. These side effects may be treatment limiting and require dose reduction or drug discontinuation objectives of the study was to assess the side effect profile of hepatitis C treatment (peginterferon alpha-2b and ribavarin) in Kashmiri patients attending the Department of Gastroenterology skims.
Methods: In this study, all consecutive patients of hepatitis C infection on peginterfron and ribavarin treatment were enrolled after written consent. The patients underwent intervention treatment taking pegylated interferon α-2b (Viraferon, Schering Plough Corp., Kenilworth, NJ) and ribavirin in accordance with the standard protocol. Patients were monitored through weekly referrals while taking the medications. A detailed history was taken and complete physical examination done each time the patient presented to the hospital necessary blood sampling was taken.
Results: During the study period of 2 years,105 Patients were enrolled 55 (52.4%) were males with a male:female ratio of 1.1:1.0. and mean age 37.6 years with a range of 13-75 years 7 patients (6.6) had a history of needle pricks, 4 patients (2.2%) of sharing same razors at barber’s shop. 4 (3.8%) patients of drug abuse; out of which 3 (2.8%) were intravenous drug abusers, Anemia occurred in 17 (16.2%) patients with requirement of dose modification w in 11 (10.4%) patients and dose stoppage in 1 (0.95%) patient in whom Hb dropped to less than 7, thrombocytopenia occurred in 27 (25.7%) patients with requirement of dose modification in 13 (12.3%) patients and dose stoppage in 1 (0.95%) patients due to platelet count decreasing to less than 30,000. Neutropenia as defined by ANC less than 1500 occurred in 22 (20.9%) patients.
Conclusions: Dose modification was required in 48 (45.7%) patients, 30 (28.5%) patients required dose modifications due to labortory abnormalities and 18 (17.1%) due to other side effects. In 8 (7.6%) patients dose was discontinued due to adverse events (including psychosis in 1, severe flu like symptoms in 3, dermatitis in 1, depression in 3).
Afdhal NH, Geahigan T. Supporting the patient with chronic hepatitis during treatment. InChronic Viral Hepatitis. Humana Press; 2002:211-232.
Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. InSeminars in liver disease. 1998 Dec;19:67-75.
McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. In Seminars in liver disease. 1998 Dec;19:57-65.
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The Lancet. 1998 Oct 31;352(9138):1426-32.
Glue P, Fang JW, Rouzier‐Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clinical Pharmacology and Therapeutics. 2000 Nov 1;68(5):556-67.
Modi M, Martin N, Heathcote JE, Nieforth K, Zeuzem S. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert opinion on investigational drugs. 2001 Dec 1;10(12):2201-13.
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 2001 Sep 22;358(9286):958-65.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine. 2002 Sep 26;347(13):975-82.
Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. British journal of ophthalmology. 2001 Oct 1;85(10):1171-3.
Hejny C, Paul S, Lawson DH, Greiner K. Retinopathy associated with high-dose interferon alfa-2b therapy American Journal of Ophthalmology. June 2001;131(6):782-7.
Nadir A, Amin A, Chalisa N, Van Thiel DH. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. Journal of viral hepatitis. 2000 Nov 1;7(6):466-70.
Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. The Journal of Laryngology and Otology. 1998 Oct 1;112(10):962-3.
Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with α-interferon and ribavirin for hepatitis C infection. The American journal of the medical sciences. 2001 Oct 31;322(4):233-5.
Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. CHEST Journal. 1994 Mar;105(3):939-41.
Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C–associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle & nerve. 2002 Jun;25(6):909-13.
Li SD, Yong S, Srinivas D, Van Thiel DH. Reactivation of sarcoidosis during interferon therapy. Journal of gastroenterology. 2002 Jan 20;37(1):50-4.
Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Japanese heart journal. 1996;37(6):905-15.
Fujiwara T, Kiura K, Ochi K, Matsubara H, Yamanari H, Shimomura H, et al. Giant negative T waves during interferon therapy in a patient with chronic hepatitis C. Internal Medicine. 2001;40(2):105-9.
Neary MP, Cort S, Bayliss MS, Ware Jr JE. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. In Seminars in liver disease. 1998 Dec;19:77-85.
Schering corporation 20000 galloping hill road Kenilworth nj07033 department of health and human service. Public health service division of antiviral drugs products food and drug administration Rockville MD 20857 Dosage and administration. Package insert 2002 NDA 20-903/S-023.
Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. Journal of Clinical Oncology. 2000 Jun 11;18(11):2316-26.
Fontana R. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Digestive Diseases. 2000;18(3):107-16.
Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002 Feb 1;35(2):433-9.
Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002 Feb 1;35(2):440-6.
Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. Journal of psychosomatic research. 2000 Nov 30;49(5):311-7.
Kraus MR, Schãfer A, Csef H, Faller H, Mõrk H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Digestive diseases and sciences. 2001 Oct 1;46(10):2060-5.
Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. Journal of viral hepatitis. 2002 Jul 1;9(4):295-303.
Hazari S, Panda SK, Gupta SD, Batra Y, Singh R, Acharya SK. Treatment of hepatitis C virus infection in patients of northern India. Journal of gastroenterology and hepatology. 2004 Sep;19(9):1058-65.
Hissar SS, Goyal A, Kumar M, Pandey C, Suneetha PV, Sood A, et al. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. Journal of medical virology. 2006 Apr;78(4):452-8.
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003 Sep 1;38(3):645-52.
Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin. Journal of gastroenterology and hepatology. 2007 Jun;22(6):832-6.
Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, et al. Peginterferon α‐2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. Journal of Gastroenterology and Hepatology. 2007 May ;22(5):645-52.
Kim KT, Han SY, Kim JH, Yoon HA, Baek YH, Kim MJ, et al. Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. The Korean journal of hepatology. 2008 Mar;14(1):36-45.
Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al. Peginterferon α‐2b plus ribavirin compared with interferon α‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International. 2004 Dec ;24(6):568-74.
Borroni G, Andreoletti M, Casiraghi MA, Ceriani R, Guerzoni P, Omazzi B, et al. Effectiveness of pegylated interferon/ribavirin combination in ‘real world’patients with chronic hepatitis C virus infection. Alimentary pharmacology & therapeutics. 2008 May ;27(9):790-7.
Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis ca randomized study of treatment duration and ribavirin dose. Annals of internal medicine. 2004 Mar;140(5):346-55.
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of hepatology. 2006 Jan;44(1):97-103.
Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of viral hepatitis. 2004 May;11(3):243-50.
Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010 Jan;138(1):116-22.
Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2010 Oct 1;52(4):1225-31.
Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C. Hepatology. 2001 Aug;34(2):395-403.
Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alfa-2a. New England Journal of Medicine. 1994 Jan 13;330(2):88-94.
Muir AJ, MHS, Bornstein JD, Paul G. Peginterferon Alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C in Blacks and Non-Hispanic Whites N Engl J Med. 2004 May;350:2265-71.